Floatz logo

Lopinavir

HIV-Associated Lipodystrophy Syndrome

Amsterdam UMC, location VUmcSmall moleculePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HIV-Associated Lipodystrophy Syndrome cohort.

Asset / SponsorPhaseRating
Efavirenz
Juan A. Arnaiz
Phase 4A
Lamivudine
Thomas Benfield
Phase 4BBB
ZIDOVUDINE
Kirby Institute
Phase 4BBB
Abacavir
Kirby Institute
Phase 4BBB
PRAVASTATIN
Kirby Institute
Phase 4BBB

View all 50 →

Same molecule, other indications

Lopinavir is also rated in:

HIV infectious diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
lipodystrophyDormant
BB
Indicative ·
69 / 100
View asset →
DyslipidemiasDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →